Regulatory News:
Ipsen (Euronext: FR0010259150)(Paris:IPN) today announced the
appointment of Sean McKercher to the company's newly established
position of Vice President of Commercial Development in North America,
effective immediately. Ipsen created this new position as a result of
the strong development of its commercial activities and partnerships
in this region and in order to better seize the large business
opportunities that arise in North America.
In his new role, Sean McKercher will report to Christophe Jean,
Ipsen's Executive Vice President and Chief Operating Officer, and will
be based in the company's Boston office. Sean McKercher will be
responsible to oversee the management of the company's various U.S.
drug partnerships and participate in the development of Ipsen's North
American business strategy and its implementation.
Sean has 25 years of experience in the pharmaceutical industry,
most recently with Abbott Laboratories. While at Abbott Lab's he
served in many leadership roles including Business Unit Manager
Specialty Pharmaceuticals Abbott Canada, Commercial Director
Pacific/Asia/Africa Region, General Manager South Africa and Region
Africa prior to his most recent set of roles in Abbott's US
pharmaceutical division. While in the US he was General Manager of the
Strategic Alliance Franchise, Abbott's $2 billion in sales
co-promotion agreement with Boehringer Ingelheim, General Manager for
Abbott's leading antibiotic Biaxin and most recently General Manager
of Marketing and Sales Operations where he led a team of 200 people in
providing support to all of Abbott's U.S. pharmaceutical commercial
teams.
About Ipsen
Ipsen is an innovation driven international specialty
pharmaceutical group with over 20 products on the market and a total
worldwide staff of nearly 4,000. The company's development strategy is
based on a combination of products in targeted therapeutic areas
(oncology, endocrinology and neuromuscular disorders) which are growth
drivers, and primary care products which contribute significantly to
its research financing. This strategy is also supported by an active
policy of partnerships. The location of its four Research and
Development centres (Paris, Boston, Barcelona, London) gives the Group
a competitive edge in gaining access to leading university research
teams and highly qualified personnel. In 2006, R&D expenditure was EUR
178.3 million, i.e. 20.7% of consolidated sales, which amounted to EUR
861.7 million while total revenues amounted to EUR 945.3 million (in
IFRS). 700 people in R&D are dedicated to the discovery and
development of innovative drugs for patient care. Ipsen's shares are
traded on Segment A of Eurolist by Euronext(TM) (stock code: IPN, ISIN
code: FR0010259150). Ipsen' s shares are eligible to the "Systeme a
Reglement Differe" ("SRD") and the Group is part of the SBF 250 index.
For more information on Ipsen, visit our website at www.ipsen.com.
Forward-looking statements
The forward-looking statements and targets contained herein are
based on Ipsen's management's current views and assumptions. Such
statements involve known and unknown risks and uncertainties that may
cause actual results, performance or events to differ materially from
those anticipated herein.
Ipsen expressly disclaims any obligation or undertaking to update
or revise any forward-looking statements, targets or estimates
contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such statements
are based, unless so required by applicable law. Ipsen's business is
subject to the risk factors outlined in its information documents
filed with the French Autorite des marches financiers.
